The drug was well tolerated ... "Advances in the early 2000s identified interferon beta (IFNβ) as a key contributor to the pathogenesis of dermatomyositis," the editorialists explained.

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...